Mundipharma presents positive findings from largest ever flutiformstudy and supportive new data on flutiform k-halerat ERS 2017
Chippenham, UK - 12 September 2017: Vectura’s partner, the Mundipharma network, presented the following data on flutiformat the European Respiratory Society International Congress (‘ERS’) 2017:
· The largest ever flutiformstudy confirms effectiveness and tolerability in real-world clinical practice (AffIRM study)
o First presentation of largest ever real-world flutiformstudy involving over 2,500 patients
o Safety profile of flutiformpMDI in practice was consistent with that demonstrated in clinical trials
o Proportion of patients with well-controlled asthma more than doubled 12 months after switching to flutiform pMDI
· New data on flutiformk-haler (125/5 microgram), Mundipharma’s novel breath-triggered aerosol inhaler currently under development, demonstrating efficient drug delivery characteristics
o flutiform k-halerachieved high levels of lung deposition of over 44% of delivered dose
o Plume force of flutiform k-haler was compared with fluticasone propionate/salmeterol xinafoate delivered via the Seretide Evohaler pMDI and Sirdupla pMDI deviceso Pharmacokinetic studies show efficacy and safety profile of new flutiform k-haler device would be comparable to flutiform pMDI device
Further details can be found on the Mundipharma web site as follows:
James Ward-Lilley, Chief Executive Officer of Vectura:
‘AffIRM is thelargest everreal-world flutiformstudy, and provides further evidence this is an effective and differentiated treatment for asthma patients. In addition, if approved, flutiform k-haler a breath-triggered inhaler device will provide another option for patients and we look forward to a conclusion of the ongoing regulatory review in Europe in due course.’
Enquiries
Vectura Group plc
+44 (0)1249 667 700
Andrew Derodra – Chief Financial Officer
Fleur Wood – Director Communications
Elizabeth Knowles – Director Investor Relations and Analysis
Consilium Strategic Communications
+44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson vectura@consilium-comms.com
About Vectura
Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading device and formulation business for inhaled airways products offering a uniquely integrated inhaled drug delivery platform. With our extensive range of device and formulation technologies, integrated capabilities and collaborations, we are a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases.
Vectura has eight inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams. The Group has a diverse portfolio of drugs in clinical development, including a number of novel and generic programmes which are partnered with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Bayer, Chiesi, Almirall, Janssen, Dynavax and Tianjin KingYork along with two wholly owned nebulised development programmes.
